

AMENDMENTS TO THE CLAIMS

Claims 1 and 2 (**Cancelled**).

3. **(Currently Amended)** A method for the treatment of scarring on the skin which comprises applying ~~to the treatment area~~ across a wound on the surface of the skin a pharmaceutical composition or biomaterial comprised of at least one hyaluronic acid derivative selected from the group consisting of an ester with an alcohol, an auto-crosslinked ester, a crosslinked derivative, a hemiester of succinic acid with hyaluronic acid, an O-sulphated derivative and an O/N sulphated derivative, optionally in association with at least one additional pharmacologically or biologically active compound.
4. **(Original)** Use of a hyaluronic acid derivative for the treatment of scarring on the skin, optionally in combination with at least one additional pharmacologically or biologically active compound.
5. **(Previously Presented)** The method according to claim 3, wherein said scarring is normotrophic scarring.
6. **(Currently Amended)** The method according to claim 3, wherein the hyaluronic acid derivative is an ester of hyaluronic acid wherein a part or all of the carboxy functions are esterified with an ~~all~~ alcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, and heterocyclic series.
7. **(Currently Amended)** The method according to claim 3, wherein the derivative of hyaluronic acid is an autocross-linked ester of hyaluronic acid wherein part or all of the carboxy groups are esterified with the alcoholic functions of the same ~~polysaccharide~~ hyaluronic acid chain or other chains.

8. **(Currently Amended)** The method according to claim 3, wherein the hyaluronic acid derivative is a cross-linked compound of hyaluronic acid wherein part or all of the carboxy groups are esterified with a polyalcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic heterocyclic series, generating cross-linking by means of spacer chains.
9. **(Currently Amended)** The method according to claim 3, wherein the hyaluronic acid derivative is an hemiesters of succinic acid or a heavy metal salt of the hemiester of succinic acid with hyaluronic acid or with a partial or total esters of hyaluronic acid.
10. **(Previously Presented)** The method according to claim 3, wherein the hyaluronic acid derivative is an O-sulphated or O/N-sulphated derivative.
11. **(Previously Presented)** The method according to claim 3, wherein the hyaluronic acid derivative is an amide derivative of hyaluronic acid.
12. **(Currently Amended)** The method according to any one of claims 3 and 5-11, wherein the hyaluronic acid derivative is in the form of a gel, ~~guide channel~~, sponge, non-woven fabric, thread, perforated or non-perforated membrane, microsphere, nanosphere, gauze pad or a ~~combination~~ combination thereof.
13. **(Previously Presented)** The method according to any one of claims 3 and 5-11, wherein the pharmacologically or biologically active substance is an antibiotic, growth factor, antimicotic, antimicrobial, antiviral agent, disinfectant, phospholipid or anaesthetic.
14. **(Original)** A method for treating scarring of the skin which comprises administering to a patient in need thereof an effective scar treatment amount of a hyaluronic acid derivative.

15. **(New)** The method according to claim 3, wherein the hyaluronic acid derivative is an ester of hyaluronic acid wherein a part or all of the carboxy functions are esterified with an alcohol of the aliphatic or aromatic series.
16. **(New)** The method according to claim 3, wherein the hyaluronic acid derivative is an ester of hyaluronic acid wherein a part or all of the carboxy functions are esterified with benzyl alcohol.
17. **(New)** The method according to claim 3, wherein the hyaluronic acid derivative is an ester of hyaluronic acid wherein 75% of the carboxy functions are esterified with benzyl alcohol.